Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 45INDUSTRY 16NETWORK 2FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 1Kidney Neoplasms 1Clear-cell metastatic renal cell carcinoma 1

Interventions

Radiotherapy 302Cisplatin 266Cyclophosphamide 230Doxorubicin 177Paclitaxel 170Vincristine 162Carboplatin 152Filgrastim 140Etoposide 139Gemcitabine 118Docetaxel 114Fluorouracil 113Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 92Leucovorin 90Gene Expression Profiling 82Granulocyte Colony-Stimulating Factor 75Specimen Handling 70Magnetic Resonance Spectroscopy 63Irinotecan 59Capecitabine 59Radiation 54Polymerase Chain Reaction 51Ifosfamide 51Rituximab 49Immunohistochemistry 49Daunorubicin 49Oxaliplatin 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Pluvicto × Clear all
NCT04663997 2026-03-27

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Canadian Cancer Trials Group

Phase 2 Active not recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms

NCT06783348 2025-01-23

RENALUT

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Not yet recruiting
48 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡